Several trials have to overcome resistance to anti-PD-1 and a potential strategy in the near future, I think, and very interesting data was also presented this year, on the cellular therapy. Because in the previous studies also in the next few years, the authors demonstrated that (tumor) infiltrating lymphocytes could be combined with immune checkpoint in patients who have previously received an anti-PD-1 or anti-CTLA-4, so immunotherapy more in general...
Several trials have to overcome resistance to anti-PD-1 and a potential strategy in the near future, I think, and very interesting data was also presented this year, on the cellular therapy. Because in the previous studies also in the next few years, the authors demonstrated that (tumor) infiltrating lymphocytes could be combined with immune checkpoint in patients who have previously received an anti-PD-1 or anti-CTLA-4, so immunotherapy more in general. Not only in melanoma really, because also in lung cancer, endometrial cancer, gynecological cancer, in the near future, several trials are to investigate the potential of T-cell infiltrating lymphocytes with immune checkpoint to overcome resistance. Thank you.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.